Slide 1: 3Q23 Earnings Presentation
3Q23 Earnings Presentation October 27, 2023
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 2022 1H23 jul/23 aug/23 sep/23 oct/23
2022 1H23 jul/23 aug/23 sep/23 oct/23
Slide 4: Warmest and totally atypical winter in over years
Warmest and totally atypical winter in over 60 years’ MEIO AMB . = : Além do calor, Brasil deve ter clima muito Brasil enfrenta onda de calor e seco: saiba os cuidados que devem ser pode ter recordes de temperatura tomados em pl eno inverno; previ 530 vai até preci mae tc ted fs ree dtr 40°C = q oe
Slide 5: Hypera Pharma grew sell-out 4.2% in 3Q23
Hypera Pharma grew sell-out 4.2%' in 3Q23 Reduction of approx. 30%? in the number of flu cases and in 10% in the volume of products in Flu, Respiratory, Pain and Fever Relevance of the categories Market Performance? (3Q23, R$ PPP)! (3Q23) 2% 1% 88% Mice Ml Market €y writs R$ PPP 5 Note: ‘Selkout PPP
Slide 6: 3Q23 Highlights
3Q23 Highlights All Non-Retail Market growth of 63.8%! Qe Interest on Equity of R$194.8 million (R$0.31/share) in 3Q23 ‘*) Part of FTSE4Good Index Series of the London Stock Exchange FTSE4Good IDIVB3 | Part of B3's IDIVERSA index Note: ‘Does not include non-recurring sales of immunoglobulin — | ) Hy
Slide 7: 3Q23 Results (R$ million)
3Q23 Results (RS million) NET REVENUE R$2,138.5 +5.0%! GROSS MARGIN 63.3%? -20bps' MARKETING EXPENSES 15.3%? -80bps! SELLING EXPENSES 11.1%? +100bps! GENERAL AND ADMINISTRATIVE EXPENSES 4.2%? +10bps! EBITDA MARGIN FROM CONTINUING OP. (excl. OTHERS) 36.2%? +70bps! NET INCOME FROM CONTINUING OPERATION
Slide 8: Cash flow and net debt bridge 3Q23
2Q23 Gross Cash Flow from PP&E Intangibles Free Cash Flow Financing Cash IOC 3Q23 Gross 3Q23 Gross 3Q23 Net Debt Cash Operations 3Q23 Flow Cash Debt
Slide 9: Slide 9